Addressing the Mounting Challenge of Patient Recruitment in Alzheimer’s Disease Clinical Trials and Other High-Need Indications

Cogstate Ltd (ASX:CGS), a cognitive science and medical technology company, today announced the latest version of its remote cognitive assessment solution for pre-screening participants in clinical trials, Precision Recruitment™ 2.1.

Precision Recruitment™ supports clinical trials in more effectively recruiting participants with specific levels of cognitive impairment using remote cognitive assessment technology. Designed to be flexibly integrated into existing recruitment workflows, Precision Recruitment™ is rapidly deployed to identify the right patients, accelerate the recruitment process and reduce costly on-site screen failures.

This new version release further optimizes patient recruitment with study-specific prescreening workflows and a delivery platform that allows for self-administered cognitive assessments on any modality including tablet-based assessments. Other important new features include:

  • Functionality allowing pre-screened participants to select an investigator site in their area, with automatic site notification for a more seamless enrolment process.
  • The ability to deploy the solution in many different languages, as required for global clinical trials.

These capabilities incorporate extensive usability testing in healthy elderly populations, ensuring high completion rates by this target population.

Of the company’s recent product release, Cogstate CEO, Brad O’Connor said, “Growing understanding of Alzheimer’s disease pathology has increased the emphasis on clinical trials toward earlier intervention in the disease, presenting significant enrollment challenges as recruitment efforts must now focus outreach strategies toward populations who are at risk for early AD. The use of remote cognitive assessment technologies to pre-screen participants is a critical element in driving efficiencies in this new paradigm of recruitment.”

"We’ve developed a technology platform that allows us to deliver our scientifically validated cognitive assessments in new settings and modalities," said Craig Gravina, Cogstate CTO. "From computer-based assessments in the clinic to self-guided at-home assessments via PC or tablet, we’ve demonstrated equivalence and are leveraging these proven cognitive measures in new ways to help solve some of the critical challenges facing clinical research."

For more information about Precision Recruitment™ visit Cogstate.com/clinical-trials

ABOUT COGSTATE

Cogstate Ltd (ASX:CGS) is a leading cognitive science company focused on optimizing the measurement of cognition to guide decision-making. Cogstate commercializes rapid, reliable and highly sensitive computerised cognitive tests for clinical trials, academic research and healthcare. In its Clinical Trials business, Cogstate provides both novel technologies and expert professional services for clinical research programs seeking to demonstrate drugs’ impact on cognition. Delivering solutions spanning the continuum from study design to final statistical analysis, Cogstate’s latest Clinical Trials offering, Precision Recruitment™ is a powerful solution based on an online pre-screening portal to accelerate the identification and engagement of qualified candidates for clinical trials in high-need indications such as Alzheimer’s disease.

For more information visit Cogstate.com or contact:AUSTRALIACogstateBrad O’ConnorChief Executive Officer+1 203 980 4204+61 411 888 347boconnor@cogstate.comorUNITED STATESCogstateLammert AlbersChief Commercial Officer+1 203 773 5010lalbers@cogstate.com

Cogstate (ASX:CGS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Cogstate.
Cogstate (ASX:CGS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Cogstate.